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Abstract 
Thyroid metastases from hepatocellular carcinoma (HCC) seldom occur and are often 
difficult to diagnose because of their asymptomatic clinical course. We evaluated a very 
rare case of solitary thyroid metastasis from HCC that showed high uptake of fluorine-18 
fluorodeoxyglucose (FDG), when imaged using fluorine-18 fluorodeoxyglucose positron 
emission tomography/computed tomography (FDG-PET/CT). The patient was a 
74-year-old man and presented with a remarkably elevated des-gamma-carboxy 
prothrombin level of 1,157 mAU/ml 22 months after hepatic lobectomy. FDG-PET/CT 
imaging revealed a hypodense tumor with high FDG uptake, with a maximum 
standardized uptake value of 5.2 in the thyroid left lobe. Solitary thyroid metastasis from 
HCC was suspected and subsequent fine needle aspiration did indeed reveal HCC. The 
patient received left thyroidectomy with left regional lymph node dissection. Two 
months after left thyroidectomy, contrast-enhanced computed tomography showed 
local recurrence, and the patient received ongoing radiotherapy treatment. To our 
knowledge, the present study is the first to demonstrate the feasibility of FDG-PET/CT in 
the diagnosis and management of clinically diagnosed, asymptomatic, solitary thyroid 
metastasis from HCC.  
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Introduction 
Hepatocellular carcinoma (HCC) is one of the most common cancers in the world. 
Various treatments are available such as hepatectomy, liver transplantation, transcatheter 
arterial chemoembolization and systemic chemotherapy. However, after the completion 
of treatment some patients present with intra- and extrahepatic metastasis [1, 2]. It is 
relatively easy to diagnose bone metastasis due to the symptom of pain, but with lung and 
adrenal gland metastasis there are often no symptoms, making diagnosis more difficult 
[3]. If extrahepatic metastasis from HCC is diagnosed, the stage is designated as stage IV 
(according to the 6th edition of the AJCC Cancer Staging Manual) [4], prognosis is poor 
and the treatment strategy changes dramatically [1–3]. Therefore, it is considered that 
early and precise diagnosis of extrahepatic metastasis from HCC is very important for 
optimal treatment [2, 3]. As far as we are aware, the present study is the first to evaluate 
the feasibility of fluorine-18 fluorodeoxyglucose positron emission tomography/ 
computed tomography (FDG-PET/CT) in the diagnosis and management of clinically 
diagnosed, asymptomatic, solitary thyroid metastasis from HCC. 
Case Report 
After a health checkup, a 74-year-old man without any symptoms was admitted for treatment due to 
an abdominal abnormality detected using ultrasound. His past medical history was unremarkable. The 
patient’s general health status was good and physical examination did not reveal anemia, jaundice or an 
abdominal or thyroid mass. Laboratory data were normal: hemoglobin level 12.0 g/dl, platelet count 
14.3 × 10
4/mm
3, albumin 3.4 g/dl, total bilirubin 0.7 mg/dl, aspartate aminotransferase 38 IU/l, alanine 
aminotransferase 17 IU/l, alkaline phosphatase 188 IU/l, gamma-glutamyltranspeptidase 26 IU/l, lactate 
dehydrogenase 164 IU/l; and creatinine level 0.83 mg/dl. Tests for the hepatitis B virus antigen and 
anti-hepatitis C virus antibody were negative. Contrast-enhanced abdominal computed tomography 
(CT) revealed heterogeneously enhanced lesions in the liver. The largest mass was roughly 6.0 × 5.5 cm 
(S3/4/1). A small 3 mm mass in the right lobe (S5) was suspected as being intrahepatic metastasis. 
Serum des-gamma-carboxy prothrombin was high at a level of 2,157 mAU/ml relative to the normal 
level of <40 mAU/ml. However, serum alpha fetoprotein was normal at a level of 4.1 ng/ml relative to 
the normal level of <6.2 ng/ml. 
Three weeks after the initial diagnosis, transcatheter arterial embolization (TAE) and 
chemo-lipiodolization (LPD) were performed prior to hepatectomy. This procedure was carried out 
because intrahepatic metastasis was suspected in the right lobe and because there was a possibility that 
the likelihood of postoperative recurrence might be decreased due to the adoption of this treatment 
strategy, such as has been found to be the case after hepatectomy of HCC following TAE [5]. Extended 
left lobectomy of the liver was performed 2 months after diagnosis because HCC was not completely 
eradicated by TAE and LPD treatment. Excision of the remaining mass revealed a well-defined, 
tan-white, firm tumor measuring 5.3 × 5.1 × 4.3 cm, with submassive necrosis and hemorrhage (fig. 1a). 
Histological analysis revealed a moderately to poorly differentiated HCC. Microscopically, the tumor 
could be seen directly invading the liver capsule. The surgical margin was 1 mm from the tumor and 
under microscopic analysis appeared negative for tumor cells. The tumor featured cells growing in 
trabecular and compact patterns (fig. 1b). Tumor invasion of the distal portal vein and distal vein was 
evident. No liver cirrhosis was noted. After complete pathological examination, the patient’s pTNM 
stage was pT3N0M0 (solitary tumor with vascular invasion) according to the 6th edition of the AJCC 
Cancer Staging Manual [4]. 
At follow-up 19 months after surgery, no local recurrence or metachronous HCC was observed. 
22 months after surgery, the des-gamma-carboxy prothrombin level was 1,157 mAU/ml, but no 
recurrent HCC was detected from the cervix to the pelvis using contrast-enhanced CT, bone 
scintigraphy and upper gastrointestinal endoscopy. Physical examination revealed no palpable neck 
nodule and the patient had no symptoms. Whole body screening was performed at 22 months after 
surgery using FDG-PET/CT. Screening revealed a hypodense tumor in the left lobe of the thyroid 
exhibiting high fluorine-18 fluorodeoxyglucose (FDG) uptake with a maximum standardized uptake 
value (SUVmax) of 5.2. Metastasis from HCC was suspected (fig. 2a, c).   
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The contrast-enhanced cervical CT performed 22 months after surgery had actually revealed a slight 
swelling of the left thyroid, but this in itself was not meaningful (fig. 2b). A solitary tumor with the 
profile of a hypoechoic heterogeneous nodule was detected in the left thyroid using ultrasonography. 
There was no metastatic focus except for the thyroid metastasis. Fine needle aspiration of the thyroid 
nodule was performed for diagnosis. Subsequent cytology revealed atypical epithelial cells with a 
granular abundant cytoplasm, hyperchromatic irregular nuclei and marked prominent nucleoli. The 
diagnosis made from the cytology was solitary metastatic HCC in the left thyroid.  
26 months after the original hepatic lobectomy the patient underwent thyroidectomy of the left lobe, 
with regional lymph node dissection, since the regional lymph node was slightly swollen and lymph 
node metastasis from HCC was suspected, which is very rare (fig. 3a). Microscopic analysis revealed 
that adipose and muscular tissue in the left lobe had been invaded by carcinoma cells and that vascular 
invasion was also prominent. Poorly differentiated HCC was arranged in trabecular and nest patterns 
(fig. 3b). The surgical margin was infiltrated by the carcinoma cells. All the lymph nodes submitted for 
examination were found to be free of carcinoma cells. Two months after the thyroidectomy local 
recurrence of HCC was detected in the remnant of the thyroid and the tumor embolus in the left 
brachiocephalic vein, using contrast-enhanced cervical CT. To date, 13 months have passed since the 
solitary thyroid metastasis was diagnosed. The patient has undergone radiation therapy but not surgery 
for the local recurrence and the tumor embolus, in accordance with the patient’s and family’s wish to 
avoid an operation. Examination of the whole body with modalities that have included FDG-PET/CT 
has so far revealed no distant metastasis, with the exception of the local recurrence of HCC in the 
thyroid. No intrahepatic metastases have been found. 
Discussion 
The present report is the first on clinically diagnosed, asymptomatic solitary thyroid 
metastasis from HCC. The diagnosis of thyroid metastasis proved very difficult due to the 
lack of symptoms and the fact that the solitary mass could not be detected clearly using 
contrast-enhanced CT. The only clue was a rise in tumor marker level, and even with 
contrast-enhanced CT it was difficult to confirm a diagnosis of thyroid metastasis. Due to 
the ability of FDG-PET/CT to detect aspects of glucose metabolism, the modality was very 
useful for discriminating between malignancy and inflammation. Another great merit of 
FDG-PET/CT is its ability to scan the whole body in a single session. We were able to 
perform the thyroidectomy of the left lobe, with regional lymph node dissection, much 
earlier than would have otherwise been possible had it not been for FDG-PET/CT. 
Previous reports have indicated that metastases from HCC have been detected at 
autopsy and in surgical specimens from lung (18.1–49.2%), lymph nodes (26.5–41.7%), 
bones (4.2–16.3%) and adrenal glands (8.4–15.4%) [6, 7]. With regard to thyroid 
metastases, the primary tumor type has been reported to be breast cancer (28%), followed 
by lymphoma (17%), lung cancer (14%) and head and neck cancer (13%) [8, 9]. The 
incidence of thyroid metastases from HCC discovered at autopsy has been reported to 
vary from 0.8 to 12% [9, 10]. Prior to our case, only 4 cases of thyroid metastases from 
HCC have been diagnosed. These cases were synchronous multiple metastases from HCC 
that included the thyroid (table 1) [10–12]. Due to clear symptoms and a palpable cervical 
mass, the antemortem diagnosis of thyroid metastasis from HCC was very easy in these 
four cases. 
FDG-PET/CT is a useful tool for the detection of metastatic liver tumors due to its 
high sensitivity. However, in the detection of HCC metastases in the liver, especially 
well-differentiated HCC metastases, it has been reported that the sensitivity of 
FDG-PET/CT is considerably lower [13, 14]. Accumulation of FDG in tumors reflects the 
activity of enzymes involved in glucose metabolism [13]. The activity of glucose-6-
phosphatase, which converts FDG-6-P to FDG, is usually high in normal liver. In 
addition, this enzyme activity in well-differentiated HCC cells results in FDG metabolism  
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at a similar rate to that in normal liver tissue. In contrast, this enzyme activity is much 
lower in undifferentiated HCC cells [13, 15]. Therefore, on this basis, it is thought that 
well-differentiated HCC usually shows low SUV and that poorly-differentiated HCC 
tends to show relatively high SUV.  
To date, no detailed reports have been published concerning the diagnosis of thyroid 
metastasis by FDG-PET/CT. However, FDG-PET/CT is considered to be useful for the 
discrimination of benign tumors and metastatic tumors, as well as changes in the degree 
of differentiation [15]. This is a major advantage in the use of FDG-PET/CT for tumor 
detection. Therefore, FDG-PET/CT is recommended for HCC patients when screening 
for extrahepatic metastases or other malignancies, prior to surgical resection or liver 
transplantation, and for the monitoring of extrahepatic metastases after chemotherapy or 
radiation therapy. 
In conclusion, our study indicated that solitary thyroid metastasis from HCC can 
occur even after hepatectomy. A strategy that uses FDG-PET/CT together with 
contrast-enhanced CT for postoperative whole body screening proved very effective. This 
approach would benefit future patients that may be at risk of distant metastasis, where 
there are no symptoms except a rise in the tumor marker level, as was found to be the case 
in our patient. 
 
 
 
Table 1. Characteristics of patients with thyroid metastases from HCC 
No. Age  Sex  FNA 
cytology 
Other metastatic 
sites 
Time to 
metastasis 
Differentiation 
of HCC 
Treatment Survival  Ref. 
1  41  M  HCC  lung, liver,  
retroperitoneal 
lymph node 
5 months  NA  NA  1 month  11 
2 54 M cancer  multiple 
intrahepatic 
7 months  poor  BSC  8 months  12 
3 67 M adeno-
carcinoma 
lung simultaneous  NA  NA  1  month  11 
4 78 M ND  bones  (shoulder 
and rib) 
simultaneous well  BSC  7  months 10 
5 73 M HCC  none  22  months  moderate 
to poor 
thyroid-
ectomy 
12 months 
(survival) 
present
case 
FNA = Fine-needle aspiration; HCC = hepatocellular carcinoma; BSC = best supportive care; NA = not available; ND = 
not done. 
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Fig. 1. Macroscopic (a) and histopathological findings (b) from analysis of the primary HCC. The cut 
surface of the tumor showed a well-defined, tan-white and firm tumor measuring 5.3 × 5.1 × 4.3 cm. 
The tumor exhibited moderately- to poorly-differentiated HCC growing in trabecular and compact 
patterns, with a grade of 2–3. Invasion of the distant portal vein and distal vein was evident. 
Hematoxylin and eosin ×100. 
 
 
 
Fig. 2. a Whole body FDG-PET/CT showing a solitary highly metabolic focus in the left side of the neck 
(arrow). b Contrast-enhanced cervical CT showing slight swelling of the left thyroid (arrow). 
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Fig. 3. Macroscopic (a) and histopathological findings (b) related to the thyroid metastasis. The cut 
surface of the tumor exhibited a well-defined, tan-white and firm tumor measuring 5.3 × 4.3 cm. The 
tumor showed poorly-differentiated HCC arranged in trabecular and nest patterns. The carcinoma cells 
could be seen invading the vascular and muscular tissue. Hematoxylin and eosin ×100. 
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